Kuick Research announced the initiation of the first mRNA lung cancer vaccine trials globally with German biotech firm BioNTech SE's (BNTX) BNT116 as a significant breakthrough in cancer treatment.Separately, Neeraj Chawla, Research head, Kuick Research, stated that at present more than 60 mRNA cancer vaccines are in clinical trials and the first commercially approved mRNA cancer vaccine can be expected to available in market by 2029.BioNTech's BNT116 is specifically engineered to combat non-small cell lung cancer or NSCLC and signifies a major progression in the field of personalized medicine.The vaccine employs messenger RNA or mRNA technology, akin to that used in COVID-19 vaccines.

Kuick Research宣布与德国生物技术公司BioNTech SE（BNTX）BNT116启动全球首个mRNA肺癌疫苗试验，这是癌症治疗的重大突破。另外，Kuick Research研究主管Neeraj Chawla表示，目前有60多种mRNA癌症疫苗正在临床试验中，预计到2029年，第一种商业批准的mRNA癌症疫苗将上市。BioNTech的BNT116是专门为对抗非小细胞肺癌或NSCLC而设计的，标志着个性化医学领域的重大进展。该疫苗采用信使RNA或mRNA技术，类似于COVID-19疫苗中使用的技术。

However, BNT116 is designed to activate the immune system to fight against cancer cells rather than targeting a virus. As the trial advances, researchers aim to establish the effectiveness of BNT116 in preventing the recurrence of lung cancer..

然而，BNT116旨在激活免疫系统以对抗癌细胞，而不是针对病毒。随着试验的进展，研究人员旨在确定BNT116在预防肺癌复发方面的有效性。。

If the results are favorable, the trials could lead to mRNA cancer vaccines being recognized as a standard treatment option globally.The BNT116 clinical trial, conducted across seven countries, will include around 130 patients at various stages of lung cancer, ranging from early to advanced or recurrent cases.

如果结果有利，这些试验可能会导致mRNA癌症疫苗被公认为全球标准治疗选择。BNT116临床试验在七个国家进行，将包括大约130名处于肺癌不同阶段的患者，从早期到晚期或复发病例不等。

These participants will receive the vaccine in conjunction with immunotherapy, a method aimed at optimizing the potential therapeutic outcomes.Kuick Research noted that more than 5 lung cancer vaccines based on mRNA platform are currently under clinical trials.At present, more than 20 of mRNA cancer vaccines are undergoing clinical trials across the globe, with the US and China at the forefront of research and development.

这些参与者将结合免疫疗法接受疫苗，这是一种旨在优化潜在治疗效果的方法。Kuick Research指出，目前有超过5种基于mRNA平台的肺癌疫苗正在进行临床试验。目前，全球有20多种mRNA癌症疫苗正在进行临床试验，美国和中国处于研发的前沿。